What happened
EndoCyclic Therapeutics announced that the US Food and Drug Administration had cleared its Investigational New Drug application for ENDO-205, an experimental non-hormonal peptide therapy for endometriosis. That regulatory step allows the company to begin its planned Phase 1 study in healthy premenopausal women. It is not FDA approval to market or prescribe ENDO-205. The company says the peptide was engineered to target endometriosis lesions, but its lesion-regression and safety claims currently come from preclinical work rather than studies in people.
Why it matters
A treatment that acts on disease tissue without suppressing hormones would address a major gap in endometriosis care. ENDO-205 has now crossed an important development threshold, but early human studies are designed primarily to assess safety and dosing. Whether the peptide can safely reduce lesions, pain or other symptoms in people with endometriosis remains unknown.
What to watch
Registration and design of the Phase 1 study, route and frequency of dosing, adverse events and pharmacokinetics, evidence that the peptide reaches its intended tissue, and later placebo-controlled results in people with endometriosis. Claims about eliminating lesions should remain described as preclinical until peer-reviewed human evidence is available.
